Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16.8M Sell
159,900
-20,100
-11% -$2.36M 1.29% 24
2025
Q4
$22.5M Sell
180,000
-6,900
-4% -$822K 1.55% 15
2025
Q3
$22.4M Buy
186,900
+14,600
+8% +$1.54M 1.86% 13
2025
Q2
$15.8M Sell
172,300
-81,800
-32% -$7.46M 1.31% 37
2025
Q1
$22.4M Sell
254,100
-51,000
-17% -$5.02M 1.92% 10
2024
Q4
$28.2M Sell
305,100
-16,300
-5% -$1.57M 2.43% 4
2024
Q3
$29.8M Buy
321,400
+2,600
+0.8% +$218K 2.3% 6
2024
Q2
$23.9M Buy
318,800
+73,500
+30% +$5.86M 1.93% 11
2024
Q1
$21.2M Buy
+245,300
New +$18.8M 1% 25

Other funds holding CRH

Payden & Rygel's CRH Position: Q1 2026 in Review

Payden & Rygel reduced its CRH (CRH) stake by 11% in Q1 2026, selling an estimated $2.36M and leaving 159,900 shares worth $16.8M. The position accounts for 1.29% of the portfolio, ranked #24.

Payden & Rygel first reported a position in CRH in Q1 2024 and has held it in 9 quarters since. The position peaked at $29.8M in Q3 2024. 1,006 funds tracked by Wall St. Rank hold CRH as of Q1 2026.

  • Payden & Rygel held 159,900 shares of CRH worth $16.8M as of Q1 2026.
  • Payden & Rygel sold 20,100 CRH shares in Q1 2026, an estimated $2.36M.
  • CRH made up 1.29% of Payden & Rygel's portfolio in Q1 2026, its #24 holding.
  • Payden & Rygel first reported a position in CRH in Q1 2024 and has held it in 9 quarters since.
  • Payden & Rygel's CRH position peaked at $29.8M in Q3 2024.
  • 1,006 funds tracked by Wall St. Rank held CRH as of Q1 2026.

Based on Payden & Rygel's 13F filing for Q1 2026, filed 12 May 2026.